Tuberculosis vaccine treatment Market – Overview
Tuberculosis (TB), is an infectious disease that usually affects the lungs caused by the bacteria Mycobacterium tuberculosis (MTB). The vaccines triggers a potent immune response against infectious diseases. Tuberculosis (TB) vaccines are for the prevention of tuberculosis.
Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of this market. Improving healthcare infrastructure, and emphasis on prevention of diseases also drives growth of this market. Additionally, government initiatives and growth strategies such as new product innovation, large pipeline products, and merger & acquisition activities taken up major market players are likely to enhance the growth of Tuberculosis vaccine treatment market.
Get Sample copy @ https://www.marketresearchfuture.com/sample_request/1684 .
According to World Health Organization (WHO), India and China are among top three countries with largest number of TB cases recorded. This rising case of TB is likely to enhance the growth of TB market globally.
However, factors such as side effects occurring from vaccinations and government approval time for vaccine, are likely to hamper the growth of tuberculosis vaccine treatment market.
Key Market Players:
Some of the key market players operating in tuberculosis vaccine treatment market are Serum Institute of India Pvt. Ltd. (India), GlaxoSmithKline plc (UK), Merck & Co., Inc.(US), Sanofi Pasteur SA (France), GreenSignal Bio Pharma Limited (India), IDT Biologics GmbH Bavarian Nordic(US), Solvay(US), Informa plc.(US) and others.
Sanofi Pasteur SA.
Headquartered in Lyon cedex, France, Sanofi Pasteur is a world leader in human vaccines. Combination vaccines that protect against multiple diseases are one of the strengths of Sanofi Pasteur’s product range. The firm offers vaccines for various diseases such as Japanese encephalitis, meningococcal meningitis, cholera, tuberculosis, typhoid, rabies, yellow fever, hepatitis A, and hepatitis B. The company has focused on various inorganic and organic growth strategies to enhance its product portfolio and gain foothold in various geographies. For instance in the year 2014, Sanofi received US Food and Drug Administration (FDA) approval for its Priftin in combination with isoniazid treatment of latent tuberculosis infection (LTBI). Additionally, in 2014, Sanofi collaborated with Statens Serum Institut of Denmark, for the development of a new vaccine for tuberculosis. These product approvals and collaborations increases the firm’s customer base and widens the company’s already existing wide product portfolio.
GlaxoSmithKline plc. Is a British pharmaceutical company, headquartered in Brentford, London, the firm has focused on various inorganic and organic growth strategies such as product launches, expansions, collaboration and acquisition to enhance its product portfolio and widen its foothold in various geographies. For instance, in 2014, GlaxoSmithKline partnered with Switzerland’s BioVersys and France’s University of Lille to develop new preclinical candidate against the airborne disease. This collaboration enhances the firm’s customer base and widens its product portfolio.
Get Amazing Discount @ https://www.marketresearchfuture.com/check-discount/1684 .
Geographically, tuberculosis vaccine treatment market is segmented into four regions: namely the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas is further segmented into North America and South America. And North America is segmented into the U.S. and Canada. Globally, the U.S. is the largest market for tuberculosis vaccine treatment owing to rising burden of TB, rising health conscious and aware of treatments of tuberculosis in the region. Additionally, increasing need for technological advancements, similarly, increasing healthcare spending is likely to grow the demand for Tuberculosis vaccine treatment market. Similarly, according to CMS (Centres for Medicare and Medicaid Services) U.S. health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016.
Europe accounts for the second largest market due to advanced technology, new product innovation, growing prevalence of chronic obstructive pulmonary disease, and rising healthcare expenditure. For instance according to Eurostat, Germany incurred healthcare expenditure of over EUR 321 billion in the year 2014.
Asia pacific region is expected to be fastest growing region in Tuberculosis vaccine treatment market owing to its growing population and increasing healthcare expenditure and increasing rate of awareness regarding the availability of myriad treatments and diagnostic methods for treating various diseases. The level of TB in China makes it a major public health problem. In 2014, there were an estimated 930,000 new cases of TB recorded in China. Each year about 2.2 million people develop TB in India and 1,423,181 people were diagnosed and registered for TB treatment.
On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare and lack of expenditure on healthcare. In the Middle East, the growth of the market is driven by increasing awareness regarding allergies and the rise in newer technologies to treat various diseases.
Table of Content:
1. Report Prologue
2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
List of Tables:
Table 1 Tuberculosis Vaccine Treatment Industry Synopsis, 2017-2023
Table 2 Global Tuberculosis Vaccine Treatment Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Tuberculosis Vaccine Treatment Market By Region, 2017-2023, (USD Million)
Table 4 Global Tuberculosis Vaccine Treatment Market By Type Of Test S, 2017-2023, (USD Million)
Table 5 Global Tuberculosis Vaccine Treatment Market By Type Of TB Vaccine, 2017-2023, (USD Million)
Table 6 Global Tuberculosis Vaccine Treatment Market By End Users, 2017-2023, (USD Million)
Table 7 North America Tuberculosis Vaccine Treatment Market By Type Of Test S, 2017-2023, (USD Million)
Table 8 North America Tuberculosis Vaccine Treatment Market By Type Of TB Vaccine, 2017-2023, (USD Million)
Table 9 North America Tuberculosis Vaccine Treatment Market By End Users, 2017-2023, (USD Million)
Table 10 U.S. Tuberculosis Vaccine Treatment Market By Type Of Test S, 2017-2023, (USD Million)
Ask Any Question @ https://www.marketresearchfuture.com/enquiry/1684 .
List of Figures:
Figure 1 Research Process
Figure 2 Segmentation For Global Tuberculosis Vaccine Treatment Market
Figure 3 Segmentation Market Dynamics For Tuberculosis Vaccine Treatment Market
Figure 4 Global Tuberculosis Vaccine Treatment Market Share, By Type Of Test S 2016
Figure 5 Global Tuberculosis Vaccine Treatment Market Share, By Type Of TB Vaccine 2016
Figure 6 Global Tuberculosis Vaccine Treatment Market Share, By End Users, 2016
Figure 7 Global Tuberculosis Vaccine Treatment Market Share, By Region, 2016
Figure 8 North America Tuberculosis Vaccine Treatment Market Share, By Country, 2016
Figure 9 Europe Tuberculosis Vaccine Treatment Market Share, By Country, 2016
Figure 10 Asia Pacific Tuberculosis Vaccine Treatment Market Share, By Country, 2016
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –